×

OncoMed Pharmaceuticals to Present at the BIO CEO and Investor and Leerink Global Healthcare Conferences in February

REDWOOD CITY, Calif., Jan. 28, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced its participation at two investor conferences during the month of February.

BIO CEO and Investor Conference

On Monday, February 9, 2015, Paul Hastings, OncoMed's Chairman and Chief Executive Officer, will present a corporate update at 11:30 am EST. The BIO CEO and Investor meeting is being held at the Waldorf Astoria in New York City.

2015 Leerink Global Healthcare Conference

On Thursday, February 12, 2015, Mr. Hastings will participate in a fireside chat to discuss recent corporate developments at the Leerink Global Healthcare Conference being held in New York City at 8:05 a.m. EST.

These presentations will be webcast live and available for replay for up to 60 days from the OncoMed website in the Investor Relations section.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has six anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), anti-Notch1 (OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28), which each target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed plans to file an Investigational New Drug application in early 2015 for anti-RSPO3 (OMP-131R10), an antibody targeting a third key cancer stem cell signaling pathway called R-spondin-LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immunotherapy product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com.

CONTACT: Media & Investors OncoMed Pharmaceuticals Michelle Corral Investor Relations and Corporate Communications michelle.corral@oncomed.com (650) 995-8373 Investors Shari Annes Annes Associates shari.annes@oncomed.com (650) 888-0902

Source:OncoMed Pharmaceuticals, Inc.